Biopharma firms with foreign exposure face disruption as Trump's tariffs loomProactive Investors • 03/27/25
Amgen (AMGN) Stock Drops Despite Market Gains: Important Facts to NoteZacks Investment Research • 03/24/25
Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?Zacks Investment Research • 03/18/25
UPLIZNA® (INEBILIZUMAB-CDON) SIGNIFICANTLY IMPROVES GENERALIZED MYASTHENIA GRAVIS SYMPTOMS IN ACETYLCHOLINE RECEPTOR AUTOANTIBODY-POSITIVE PATIENTS OVER 52 WEEKSPRNewsWire • 03/13/25
Take the Zacks Approach to Beat the Markets: NioCorp, AngloGold, Amgen in FocusZacks Investment Research • 03/10/25
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITISPRNewsWire • 03/08/25
Amgen (AMGN) Up 2.9% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 03/06/25
AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmGlobeNewsWire • 03/06/25